Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab
Compared to H2AR use, PPI use was associated with dose-dependent poorer oncological outcomes in metastatic CRC patients treated with bevacizumab.
Authors
- Chuan‐Yin Fang
- Ta-Wen Hsu
- Chin-Chia Wu (ORCID: https://orcid.org/0000-0002-6499-1072)
- Yu‐Tso Liao (ORCID: https://orcid.org/0000-0002-9329-1235)
- Wen‐Yen Chiou (ORCID: https://orcid.org/0000-0002-5541-6834)
- Chuan-Sheng Hung (ORCID: https://orcid.org/0009-0008-6290-0967)
- Shih‐Kai Hung (ORCID: https://orcid.org/0000-0002-4945-528X)
- Pei-Tsen Chen
- Jui‐Hsiu Tsai (ORCID: https://orcid.org/0000-0001-7335-4131)
Institutions
- National Sun Yat-sen University (TW)
- Tzu Chi University (TW)
- Taipei Tzu Chi Hospital (TW)
- Chia-Yi Christian Hospital (TW)
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-02
- DOI
- https://doi.org/10.3390/cancers16193378
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.42